Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Treatment of pediatric patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) with obecabtagene autoleucel (obe-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy: Preliminary findings from the Phase Ib/II CATULUS trial

Sara Ghorashian, Michael Pulsipher, Juliana Silva, Alba Rubio-San-Simón, Amanda Lipsitt, Denise Bonney, Cristina Díaz-de-Heredia, Geoff Shenton, Justin Shang, Kapil Saxena, Wolfram Brugger, Pierre Lao-Sirieix, Shannon Maude

Blood (2025) 146 (Supplement 1): 3337.

https://doi.org/10.1182/blood-2025-3337

Published: 2025

Journal Articles

High event-free (EFS) and overall survival (OS) after non-total body irradiation (TBI) conditioning and allogeneic hematopoietic cell transplantation (HCT) in next-generation-sequencing minimal residual disease (NGS-MRD) negative B-acute lymphoblastic leukemia (B-ALL): Results from the EndRAD trial (PTCTC ONC1701)

Blood (2025) 146 (Supplement 1): 163.

https://doi.org/10.1182/blood-2025-163

Published: 2025

Journal Articles

Bone marrow next generation sequencing minimal residual disease (NGS-MRD) positivity pre-allogeneic hematopoietic cell transplantation (HCT) predicts outcomes for patients with B-cell acute lymphoblastic leukemia (B-ALL): A planned analysis from the ptctc ONC1401 trial

Amanda Johnson, Yuxin Zhao, Xi Qiao, J. Gregory Dolan, Karely Van Thiel Berghuijs, Julie-An Talano, Carrie Kitko, Sonali Chaudhury, Christopher Dvorak, Nahal Lalefar, Nancy Bunin, Neena Kapoor, Eric Anderson, Alice Bertaina, Allyson Flower, Michael Pulsipher, Hisham Abdel-Azim

Blood (2025) 146 (Supplement 1): 511.

https://doi.org/10.1182/blood-2025-511

Published: 2025

Journal Articles

Highly efficient collection and manufacture of autologous HSC gene therapy cell product for patients with sickle cell disease using a lentiviral vector containing a shmir targeting BCL11a

Blood (2025) 146 (Supplement 1): 6094.

https://doi.org/10.1182/blood-2025-6094

Published: 2025

Journal Articles

MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD

Blood (2018) 131 (25): 2846–2855.

https://doi.org/10.1182/blood-2018-01-822957

Published: 2018

Includes: Supplemental data

Journal Articles

Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation

Richard Aplenc, Mei-Jie Zhang, Lillian Sung, Xiaochun Zhu, Vincent T. Ho, Kenneth Cooke, Christopher Dvorak, Gregory Hale, Luis M. Isola, Hillard M. Lazarus, Philip L. McCarthy, Richard Olsson, Michael Pulsipher, Marcelo C. Pasquini, Nancy Bunin

Blood (2014) 123 (22): 3504–3511.

https://doi.org/10.1182/blood-2013-03-490334

Published: 2014

Includes: Supplemental data

Journal Articles

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era

Blood (2012) 119 (17): 4083–4090.

https://doi.org/10.1182/blood-2012-02-409763

Published: 2012

Journal Articles

Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels

Jakub Tolar, MD, PhD, H. Joachim Deeg, M.D., Sally Arai, MD, Mitchell Horwitz, MD, Joseph H. Antin, MD, John M. McCarty, MD, Roberta H. Adams, MD, Mary Eapen, MBBS, Marian Ewell, ScD, Eric Leifer, PhD, Iris Gersten, MS, Shelly L Carter, ScD, Mary M. Horowitz, MD, Dennis L Confer, MD, Ryotaro Nakamura, MD, Michael Pulsipher, MD, Nancy L DiFronzo, PhD, Paolo Anderlini, MD

Blood (2011) 118 (21): 3009.

https://doi.org/10.1182/blood.V118.21.3009.3009

Published: 2011

Journal Articles

Increased Incidence of Chronic Graft-Versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial

Blood (2011) 118 (21): 1.

https://doi.org/10.1182/blood.V118.21.1.1

Published: 2011

Journal Articles

Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM).

Marcello Rotta, MD, Barry E Storer, Thoralf Lange, MD, Michael Pulsipher, MD, Judith Shizuru, MD, PhD, Benedetto Bruno, MD, PhD, Peter A. McSweeney, MD, Edward Agura, MD, Thomas Chauncey, MD, PhD, Frederick R Appelbaum, MD, William Bensinger, MD, Brenda M Sandmaier, MD, Rainer F Storb, George E. Georges, MD, David G Maloney, MD, PhD

Blood (2009) 114 (22): 3391.

https://doi.org/10.1182/blood.V114.22.3391.3391

Published: 2009

Journal Articles

A Randomized 3-Arm Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial.

Brenda M. Sandmaier, MD, Michael Maris, MD, Barry Storer, PhD, Lars Vindelov, MD, Amelia Langston, MD, James C. Wade, MD, MPH, Wolfgang A. Bethge, MD, Michael Pulsipher, MD, Thoralf Lange, MD, Thomas Chauncey, MD, Finn Petersen, MD, Kai Hübel, MD, Ann Woolfrey, MD, Mary E.D. Flowers, MD, David G. Maloney, MD, PhD, Rainer F. Storb, MD

Blood (2009) 114 (22): 348.

https://doi.org/10.1182/blood.V114.22.348.348

Published: 2009

Journal Articles

Impact of Conditioning Regimen in Allogeneic Hematopoetic Stem Cell Tansplant for Children with AML beyond the First Complete Remission: Total Body Irradiation Versus Busulfan- a Pediatric Blood and Marrow Transplant Consortium (PBMTC) Study

India Sisler, MD, Jennifer Domm, MD, Robin Ryan, John E. Levine, MD, Michael Pulsipher, MD, Paul R. Haut, MD, Kirk R. Schultz, MD, Tatsuki Koyama, Elizabeth Koehler, Haydar Frangoul

Blood (2008) 112 (11): 3006.

https://doi.org/10.1182/blood.V112.11.3006.3006

Published: 2008

Journal Articles

Similar Outcomes Using Myeloablative Versus Reduced Intensity and Non-Myeloablative Allogeneic Transplant Preparative Regimens for AML or MDS: From the Center for International Blood and Marrow Transplant Research

Selina Luger, MD, Olle Ringden, MD, Waleska S. Peréz, MPH, Mei-Jie Zhang, PhD, John F. DiPersio, MD, PhD, Jorge Sierra, MD, Martin Tallman, MD, Daniel J. Weisdorf, MD, Michael Pulsipher, MD

Blood (2008) 112 (11): 348.

https://doi.org/10.1182/blood.V112.11.348.348

Published: 2008

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years.

Blood (2008) 112 (11): 2162.

https://doi.org/10.1182/blood.V112.11.2162.2162

Published: 2008

Journal Articles

Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

Mohamed L. Sorror, MD, MS, Barry Storer, PhD, Brenda M. Sandmaier, MD, Michael Maris, MD, Thomas Chauncey, MD, Richard T. Maziarz, MD, Michael Pulsipher, MD, Judith Shizuru, MD, PhD, Dietger Niederwieser, MD, Edward Agura, MD, James C. Wade, MD, MPH, Amelia A Langston, MD, Rainer F. Storb, MD, David G. Maloney, MD, PhD

Blood (2008) 112 (11): 2147.

https://doi.org/10.1182/blood.V112.11.2147.2147

Published: 2008

Journal Articles

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia

Blood (2008) 112 (11): 149.

https://doi.org/10.1182/blood.V112.11.149.149

Published: 2008

Journal Articles

Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.

Marcello Rotta, MD, Barry Storer, PhD, Firoozeh Sahebi, MD, Judith A. Shizuru, MD, PhD, Benedetto Bruno, MD, PhD, Thoralf Lange, MD, Peter A. McSweeney, MD, Michael Pulsipher, MD, Parameswaran Hari, MD, MS, Richard Thomas Maziarz, MD, Edward Agura, MD, Thomas Chauncey, MD, PhD, Frederick Appelbaum, MD, William Bensinger, MD, Brenda Sandmaier, MD, PhD, Rainer Storb, MD, David G. Maloney, MD, PhD

Blood (2008) 112 (11): 1130.

https://doi.org/10.1182/blood.V112.11.1130.1130

Published: 2008

Journal Articles

Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL).

Blood (2007) 110 (11): 173.

https://doi.org/10.1182/blood.V110.11.173.173

Published: 2007

Journal Articles

Long-Term Follow Up of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

Mohamed L. Sorror, Barry Storer, Brenda M. Sandmaier, Michael B. Maris, Judith Shizuru, Jose Leis, Edward Agura, Thomas Chauncey, Michael Pulsipher, Peter McSweeney, James Wade, Benedetto Bruno, Amelia Langston, Jerry Radich, Dietger Niederwieser, Karl Blume, Rainer Storb, David G. Maloney

Blood (2007) 110 (11): 1662.

https://doi.org/10.1182/blood.V110.11.1662.1662

Published: 2007

Journal Articles

Reversal of Low Chimerism Following Nonmyeloablative (NM) Hematopoietic Cell Transplantation (HCT) Using Pentostatin and Donor Lymphocyte Infusions (DLI).

Monica Thakar, MD, Barry Storer, PhD, Thomas Chauncey, MD, PhD, Michael Pulsipher, MD, David Maloney, MD, PhD, Rainer Storb, MD, Brenda Sandmaier, MD

Blood (2007) 110 (11): 480.

https://doi.org/10.1182/blood.V110.11.480.480

Published: 2007

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Treatment of pediatric patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) with obecabtagene autoleucel (obe-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy: Preliminary findings from the Phase Ib/II CATULUS trial

Bone marrow next generation sequencing minimal residual disease (NGS-MRD) positivity pre-allogeneic hematopoietic cell transplantation (HCT) predicts outcomes for patients with B-cell acute lymphoblastic leukemia (B-ALL): A planned analysis from the ptctc ONC1401 trial

Highly efficient collection and manufacture of autologous HSC gene therapy cell product for patients with sickle cell disease using a lentiviral vector containing a shmir targeting BCL11a

MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD

Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era

Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From Unrelated Donors in Severe Aplastic Anemia (SAA): Serious and Unexpected Adverse Events in Pre-Defined Cyclophosphamide (CY) Dose Levels

Nonmyeloablative Allogeneic HCT From Unrelated Donors for Multiple Myeloma (MM).

Impact of Conditioning Regimen in Allogeneic Hematopoetic Stem Cell Tansplant for Children with AML beyond the First Complete Remission: Total Body Irradiation Versus Busulfan- a Pediatric Blood and Marrow Transplant Consortium (PBMTC) Study

Similar Outcomes Using Myeloablative Versus Reduced Intensity and Non-Myeloablative Allogeneic Transplant Preparative Regimens for AML or MDS: From the Center for International Blood and Marrow Transplant Research

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years.

Sustained Graft-Versus-Lymphoma Effect among Patients (pts) with Mantle Cell Lymphoma (MCL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia

Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.

Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL).

Long-Term Follow Up of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).

Reversal of Low Chimerism Following Nonmyeloablative (NM) Hematopoietic Cell Transplantation (HCT) Using Pentostatin and Donor Lymphocyte Infusions (DLI).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only